{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:39:08Z","timestamp":1779111548811,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020540","name":"Coherus Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02636-5","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:11Z","timestamp":1694699411000},"page":"4889-4906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7460-6781","authenticated-orcid":false,"given":"Hong","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Civoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna","family":"Tatarewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Vandenkoornhuyse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Finck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"suppl 5","key":"2636_CR1","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138.","journal-title":"Ann Oncol"},{"key":"2636_CR2","unstructured":"UDENYCA (pegfilgrastim-cbqv) injection, for subcutaneous use. Package insert. Coherus BioSciences Inc.; 2022."},{"key":"2636_CR3","unstructured":"Neulasta (pegfilgrastim) injection single-dose prefilled syringe. Package Insert. Amgen, Inc.; 2021."},{"issue":"1","key":"2636_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u201332.","journal-title":"Eur J Cancer"},{"key":"2636_CR5","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hematopoietic growth factors Version 2.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed April 23, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network\u00ae (NCCN\u00ae)"},{"issue":"4","key":"2636_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/cts.12777","volume":"13","author":"J Harrold","year":"2020","unstructured":"Harrold J, Gisleskog PO, Perez-Ruixo JJ, et al. Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome. Clin Transl Sci. 2020;13(4):807\u201317.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2636_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cyto.2014.08.003","volume":"71","author":"VK Singh","year":"2015","unstructured":"Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. Cytokine. 2015;71(1):22\u201337.","journal-title":"Cytokine"},{"issue":"4","key":"2636_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.rpor.2011.05.001","volume":"16","author":"M L\u00f3pez","year":"2011","unstructured":"L\u00f3pez M, Mart\u00edn M. Medical management of the acute radiation syndrome. Rep Pract Oncol Radiother. 2011;16(4):138\u201346.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"3","key":"2636_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/14656566.2019.1702968","volume":"21","author":"VK Singh","year":"2020","unstructured":"Singh VK, Seed TM. Pharmacological management of ionizing radiation injuries: current and prospective agents and targeted organ systems. Expert Opin Pharmacother. 2020;21(3):317\u201337.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2636_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40487-022-00207-2","volume":"10","author":"SZ Humphreys","year":"2022","unstructured":"Humphreys SZ, Geller RB, Walden P. Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit. Oncol Ther. 2022;10(2):351\u20136.","journal-title":"Oncol Ther"},{"key":"2636_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.","journal-title":"BMC Cancer"},{"issue":"4","key":"2636_CR12","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.","journal-title":"Rand Health Q"},{"issue":"10","key":"2636_CR13","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1007\/s12325-020-01459-y","volume":"37","author":"B Finck","year":"2020","unstructured":"Finck B, Tang H, Civoli F, Hodge J, O\u2019Kelly H, Vexler V. Pharmacokinetic and pharmacodynamic equivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. Adv Ther. 2020;37(10):4291\u2013307.","journal-title":"Adv Ther"},{"key":"2636_CR14","unstructured":"FDA approves UDENYCA\u00ae autoinjector. Press release. Redwood City, CA: Coherus BioSciences, Inc.; 2023."},{"issue":"10","key":"2636_CR15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jsps.2021.09.004","volume":"29","author":"A Roy","year":"2021","unstructured":"Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector - A smart device for emergency cum personal therapy. Saudi Pharm J. 2021;29(10):1205\u201315.","journal-title":"Saudi Pharm J"},{"issue":"3","key":"2636_CR16","first-page":"100","volume":"9","author":"T Hibino","year":"2020","unstructured":"Hibino T, Yoshida T, Sagawa A, Masuda I, Fukuda T. Qualitative survey-based evaluation of operability and convenience for the etanercept biosimilar YLB113 in a unique injection pen in patients with rheumatoid arthritis. GaBiJournal. 2020;9(3):100\u20137.","journal-title":"GaBiJournal"},{"key":"2636_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/PPA.S154181","volume":"12","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, D\u2019Heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018;12:1193\u2013202.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2636_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40744-020-00216-5","volume":"7","author":"N Rekaya","year":"2020","unstructured":"Rekaya N, Vicik SM, Hulesch BT, McDonald LL. Enhancement of an auto-injector device for self-administration of etanercept in patients with rheumatoid arthritis confers emotional and functional benefits. Rheumatol Ther. 2020;7(3):537\u201352.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"2636_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1517\/14712590903530633","volume":"10","author":"J Borr\u00e1s-Blasco","year":"2010","unstructured":"Borr\u00e1s-Blasco J, Gracia-P\u00e9rez A, Rosique-Robles JD, Caster\u00e1 MD, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10(3):301\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"2636_CR20","unstructured":"Ypsomed Group. YpsoMate \u2013 the 2-step autoinjector. March 31, 2022. https:\/\/yds.ypsomed.com\/en\/injection-systems\/auto-injectors\/ypsomate.html. Accessed 24 May 2023."},{"issue":"1","key":"2636_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1208\/s12248-019-0386-y","volume":"22","author":"F Civoli","year":"2019","unstructured":"Civoli F, Kasinath A, Cai XY, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. AAPS J. 2019;22(1):7.","journal-title":"AAPS J"},{"issue":"3","key":"2636_CR22","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/s12325-021-02024-x","volume":"39","author":"F Civoli","year":"2022","unstructured":"Civoli F, Finck B, Tang H, Hodge J, O\u2019Kelly H, Vexler V. Biosimilar pegfilgrastim-cbqv demonstrated similar immunogenicity to pegfilgrastim in healthy subjects across three randomized clinical studies. Adv Ther. 2022;39(3):1230\u201346.","journal-title":"Adv Ther"},{"issue":"5","key":"2636_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295\u2013306.","journal-title":"Clin Pharmacokinet"},{"key":"2636_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/PPA.S50583","volume":"8","author":"F Schwarzenbach","year":"2014","unstructured":"Schwarzenbach F, Dao Trong M, Grange L, et al. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:199\u2013209.","journal-title":"Patient Prefer Adherence"},{"issue":"supp 4","key":"2636_CR25","doi-asserted-by":"publisher","first-page":"S1071","DOI":"10.1016\/j.annonc.2020.08.1531","volume":"31","author":"M Metz","year":"2020","unstructured":"Metz M, Semsek D, Rogmans G, Hutschenreuter U, Fietz T, Harde J, et al. Patient, nurse and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector (OBI) in cancer patients. Ann Oncol. 2020;31(supp 4):S1071 (Abstract 1884P).","journal-title":"Ann Oncol"},{"key":"2636_CR26","unstructured":"The Business Research Company. Autoinjectors global market report 2023\u2014by type (disposable autoinjectors, reusable autoinjectors), by therapy (rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, other therapies), by route of administration (subcutaneous, intramuscular), by distribution channel (online retailer, pharmacy), by end user (home care settings, hospitals and clinics, other end-users)\u2014market size, trends, and global forecast 2023\u20132032. January 2023. https:\/\/www.thebusinessresearchcompany.com\/report\/autoinjectors-global-market-report. Accessed 24 May 2023."},{"key":"2636_CR27","unstructured":"Autoinjectors market size to hit around USD 247.3 BN by 2030. Press release. Globe Newswire; November 22, 2022. https:\/\/www.globenewswire.com\/en\/news-release\/2022\/11\/22\/2560680\/0\/en\/Autoinjectors-Market-Size-to-Hit-Around-USD-247-3-BN-by-2030.html. Accessed 24 May 2023."},{"key":"2636_CR28","unstructured":"US Food and Drug Administration. Guidance for Industry. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. 2016. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM397017.pdf. Accessed 24 May 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02636-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02636-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:08:17Z","timestamp":1697058497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02636-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2636"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02636-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"31 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hong Tang, Suzanna Tatarewicz, Nathalie Vandenkoornhuyse,\u00a0and Barbara Finck are employees of and own stock in Coherus BioSciences (Redwood City, CA). Francesca Civoli is a former employee and owns stock in Coherus BioSciences (Redwood City, CA). Francesca is currently affiliated with Francesca Civoli Consulting LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Advarra Institutional Review Board reviewed and approved the protocol and informed consent form (IRB Registration Number: IRB0000971). All applicable laws and regulations were followed when conducting the study, including the International Conference for Harmonisation E6 Guideline on Good Clinical Practice. All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}